NCT07156578View on ClinicalTrials.gov

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 3, 2025

Primary Completion Date

April 15, 2028

Study Completion Date

April 15, 2028

Conditions
Hypothalamic Obesity
Interventions
DRUG

Bivamelagon

daily dose of oral bivamelagon

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT07156578 - A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) | Biotech Hunter | Biotech Hunter